Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

Does using Endocuff Vision device increase the ability to find bowel polyps in bowel cancer screening endoscopy?

ABSTRACT: See https://www.cancerresearchuk.org/about-cancer/find-a-clinical-trial/a-study-looking-device-that-may-help-find-manage-polyps-bowel-during-cancer-screening-test-b-adenoma

DISEASE(S): Gastroenterology,Gastroenterology Cancer/ Malignant Neoplasms Of Digestive Organs,Oral And Gastrointestinal/ Other Diseases Of The Digestive System

PROVIDER: 2415228 | ecrin-mdr-crc |

REPOSITORIES: ECRIN MDR

ACCESS DATA

Json Xml

Similar Datasets

Improved adenoma detection with Endocuff Vision: the ADENOMA randomised controlled trial.

Project description:OBJECTIVE:Low adenoma detection rates (ADR) are linked to increased postcolonoscopy colorectal cancer rates and reduced cancer survival. Devices to enhance mucosal visualisation such as Endocuff Vision (EV) may improve ADR. This multicentre randomised controlled trial compared ADR between EV-assisted colonoscopy (EAC) and standard colonoscopy (SC). DESIGN:Patients referred because of symptoms, surveillance or following a positive faecal occult blood test (FOBt) as part of the Bowel Cancer Screening Programme were recruited from seven hospitals. ADR, mean adenomas per procedure, size and location of adenomas, sessile serrated polyps, EV removal rate, caecal intubation rate, procedural time, patient experience, effect of EV on workload and adverse events were measured. RESULTS:1772 patients (57% male, mean age 62 years) were recruited over 16 months with 45% recruited through screening. EAC increased ADR globally from 36.2% to 40.9% (P=0.02). The increase was driven by a 10.8% increase in FOBt-positive screening patients (50.9% SC vs 61.7% EAC, P<0.001). EV patients had higher detection of mean adenomas per procedure, sessile serrated polyps, left-sided, diminutive, small adenomas and cancers (cancer 4.1% vs 2.3%, P=0.02). EV removal rate was 4.1%. Median intubation was a minute quicker with EAC (P=0.001), with no difference in caecal intubation rate or withdrawal time. EAC was well tolerated but caused a minor increase in discomfort on anal intubation in patients undergoing colonoscopy with no or minimal sedation. There were no significant EV adverse events. CONCLUSION:EV significantly improved ADR in bowel cancer screening patients and should be used to improve colonoscopic detection. TRIAL REGISTRATION NUMBER:NCT02552017, Results; ISRCTN11821044, Results.

| S-EPMC6352411 | biostudies-literature

Endocuff Vision improves adenoma detection rate in a large screening-related cohort.

Project description:Background and study aims Endocuff Vision (ECV) increases adenoma detection rate (ADR) in randomized clinical trials; however, observational effectiveness data are lacking. We evaluated the effectiveness, safety, and practical aspects of ECV use in a large screening-related real-world cohort. Patients and methods In this observational study, patients undergoing screening-related colonoscopy from November 2018 to April 2019 comprised the baseline period, and those undergoing it from June to November 2019 comprised the ECV period, where ECV use was discretionary. The primary outcome was ADR, compared: 1) between ECV use and standard colonoscopy across both periods; and 2) between time periods. Secondary outcomes included indication-specific ADR, sessile serrated ADR (SSADR), cecal intubation rate (CIR), procedure times, patient comfort scores, and sedation use. Multilevel logistic regression was performed, yielding adjusted odds ratios (AOR) with 95 % confidence intervals (CIs). Results In 15,814 colonoscopies across both time periods, ADR was 46.7 % with standard colonoscopy and 54.6 % when ECV was used ( P < 0.001). Endoscopists used ECV in 77.6 % of procedures in the ECV period, during which overall ADR rose to 53.2 % compared to 46.3 % in the baseline period ( P < 0.001). ECV use was significantly associated with higher ADR (AOR 1.24, 95 % CI 1.10 to 1.40) after adjusting for relevant covariates including time period. ECV use did not result in lower CIR, longer procedure time, increased sedation use, or poorer comfort scores. Conclusions ECV use is associated with improved ADR without negatively impacting other key procedure and patient-related factors. Future studies should evaluate the cost-effectiveness of incorporating ECV into routine screening-related practice.

| S-EPMC8545492 | biostudies-literature

To find target miRNA of Zeb1

Project description:To find target miRNA of Zeb1

| PRJNA853954 | ENA

Family Investigation of Nephropathy and Diabetes (FIND)

Project description:Family Investigation of Nephropathy and Diabetes (FIND)

| PRJNA75509 | ENA

Anticipated Regret To Increase Colorectal cancer screening (ARTICS)

Project description:See https://www.cancerresearchuk.org/about-cancer/find-a-clinical-trial/a-study-looking-at-attitudes-to-health-and-bowel-screening-in-scotland-artics

| 2423094 | ecrin-mdr-crc

To find target genes of Zeb1 [CUT&Tag-Seq]

Project description:To find target genes of Zeb1 [CUT&Tag-Seq]

| PRJNA853063 | ENA

Genome-wide gene expression analysis to find ZDHHC11 targets

Project description:Genome-wide gene expression analysis to find ZDHHC11 targets

| PRJNA903280 | ENA

Isolation of fungi using the diffusion chamber device FIND technology.

Project description:Fungi are an important source of bioactive metabolites. The Fungal one-step IsolatioN Device (FIND) technology allows the isolation of rare fungi from terrestrial and marine samples. The FIND comprises a multi-chambered micro agar plate, where initially only one fungal part (e.g., hyphal cell, mycelial fragment or spore) is located in each chamber. After inoculation the device is placed back into the original natural environment of sample collection, to ensure favourable growth conditions. Experiments were carried out with terrestrial soil and marine sediment, as well as sea water samples to validate this method. This yielded axenic cultures of 12 different filamentous fungi, one of them being the marine-adapted fungal strain Heydenia cf. alpina. The latter produced two new terpenoids, which are the first secondary metabolites from this genus.

| S-EPMC6774082 | biostudies-literature

5-ALA in bowel cancer surgery

Project description:See https://www.cancerresearchuk.org/about-cancer/find-a-clinical-trial/a-study-of-5ala-in-bowel-cancer-surgery-glisten

| 2423999 | ecrin-mdr-crc

Public perceptions of bowel cancer screening

Project description:See https://www.cancerresearchuk.org/about-cancer/find-a-clinical-trial/trial-looking-what-people-think-information-they-receive-nhs-bowel-cancer-screening-programme

| 2424656 | ecrin-mdr-crc

OmicsDI is part of the ELIXIR infrastructure

OmicsDI is an Elixir interoperability service. Learn more ›

Tweets

OmicsDI Databases

PRIDE
PeptideAtlas
MassIVE
JPOST Repository
Physiome Model Repository

EGA
EVA
ENA
LINCS
PAXDB
Cell Collective

MetaboLights
Metabolomics Workbench
MetabolomeExpress
GNPS
BioModels
FAIRDOMHub

ArrayExpress
dbGaP
ExpressionAtlas
GEO
NODE

Information

Databases
Help
API
Contact us
Code on GitHub
Terms of use
Submit Data